Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) Equity Ratio: 2019-2025

Historic Equity Ratio for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to 0.72.

  • Allogene Therapeutics' Equity Ratio fell 8.91% to 0.72 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.72, marking a year-over-year decrease of 8.91%. This contributed to the annual value of 0.77 for FY2024, which is 3.44% down from last year.
  • Per Allogene Therapeutics' latest filing, its Equity Ratio stood at 0.72 for Q3 2025, which was down 2.07% from 0.73 recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Equity Ratio peaked at 0.91 during Q2 2021, and registered a low of 0.72 during Q3 2025.
  • For the 3-year period, Allogene Therapeutics' Equity Ratio averaged around 0.78, with its median value being 0.79 (2024).
  • As far as peak fluctuations go, Allogene Therapeutics' Equity Ratio rose by 3.00% in 2021, and later fell by 10.79% in 2023.
  • Allogene Therapeutics' Equity Ratio (Quarterly) stood at 0.88 in 2021, then fell by 7.81% to 0.81 in 2022, then fell by 1.83% to 0.80 in 2023, then declined by 3.44% to 0.77 in 2024, then declined by 8.91% to 0.72 in 2025.
  • Its last three reported values are 0.72 in Q3 2025, 0.73 for Q2 2025, and 0.76 during Q1 2025.